Cite this answer
PEG-MGF: quick citable summary
PEG-MGF is listed by PeptaHub as a muscle & growth peptide with a reclassification pending legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “PEG-MGF: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/peg-mgf. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/peg-mgf.
What is PEG-MGF?
PEG-MGF is a PEGylated form of Mechano Growth Factor, an IGF-1 splice variant. Most published E-peptide work is cardiac rather than skeletal muscle, no pharmacokinetic study of PEG-MGF exists in any species, and no human trial has been conducted.
Overview
PEG-MGF (PEGylated Mechano Growth Factor) is a synthetic, polyethylene glycol-modified form of MGF, which is itself a splice variant of IGF-1 (Insulin-like Growth Factor 1) expressed in muscle in response to mechanical stress. Pegylation is used to slow clearance, but no published pharmacokinetic study of PEG-MGF exists in any species, so the specific half-life figures circulated for it are unsourced.
Mechanism of action
MGF is generated by alternative splicing of the IGF-1 gene in mechanically stressed muscle. Its unique C-terminal E-domain peptide activates quiescent muscle satellite cells — the resident stem cells responsible for muscle repair and hypertrophy. The MGF E-peptide acts distinctly from mature IGF-1: in myoblast culture it promoted proliferation while mature IGF-1 drove differentiation, and the E-peptide does not act through the IGF-1 receptor in the way mature IGF-1 does (Yang and Goldspink, FEBS Lett 2002). The receptor for the E-peptide has not been definitively identified. The PEG modification is intended to shield the peptide from proteolytic degradation and renal clearance, but no pharmacokinetic study of PEG-MGF has been published, so the extent of any half-life extension is unquantified.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| muscle repair and satellite cell activation (research) | subcutaneous | 200–400 mcg | 2–3 times per week | Community-reported range with no study behind it. No human trial or pharmacokinetic study of PEG-MGF has been published, so neither the dose, the frequency nor the cycle length is trial-derived. Research use only. |
| muscle repair (intramuscular, research) | intramuscular | 200–400 mcg | 2–3 times per week | IM injection into target muscle group studied for localized satellite cell activation. Research use only. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert PEG-MGF research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? The PEG-MGF dose calculator is preloaded with these ranges, or use the general dose unit converter.
Research summary
Worth noting up front: most of the published MGF E-peptide work is cardiac, not skeletal muscle. The E-domain peptide inhibited cardiomyocyte apoptosis and preserved cardiac function after myocardial infarction in animals (Mavrommatis, Mol Cell Biochem 2013), delayed decompensation after infarction (Shioura 2014), and improved cardiac function when delivered locally via polymeric microstructures (Peña, Biomaterials 2015). For skeletal muscle, the cited evidence is myoblast culture showing that the E peptide promotes proliferation while mature IGF-1 drives differentiation (Yang and Goldspink, FEBS Lett 2002). No study cited here reports increased fiber cross-sectional area or reduced necrosis markers after PEG-MGF. No human clinical trial of PEG-MGF has been completed, and no pharmacokinetic study of it has been published in any species.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with PEG-MGF for synergistic effects.
Legal status
PEG-MGF cannot legally be compounded in the US today. It is one of 12 peptides the FDA removed from Category 2 of the interim 503A bulk drug substances list on April 15, 2026, effective within seven calendar days, because the original nominators withdrew their nominations. Removal from Category 2 is not the same as being added to the Section 503A Bulks List or placed in Category 1, and the FDA has been explicit that it does not by itself make a substance eligible for compounding — enforcement discretion extends only to Category 1, and these substances were never in Category 1. PEG-MGF, which the FDA lists as pegylated mechano growth factor, was not among the seven peptides heard on July 23-24, 2026; the FDA has stated the Pharmacy Compounding Advisory Committee will reconvene before the end of February 2027 to consider it alongside GHK-Cu, Melanotan II, LL-37, and dihexa acetate. Industry commentary has generally expected PEG-MGF to remain restricted. PCAC is advisory and formal rulemaking afterward typically takes 12 to 24 months. PEG-MGF is not FDA-approved, is otherwise sold by research peptide suppliers as a laboratory compound, and is prohibited by WADA in competitive sport. Verify current federal and state rules before relying on access claims.
Sourcing & access
Reclassification in progress
PEG-MGFis one of 12 peptides the FDA removed from its Category 2 “do not compound” list on April 15, 2026, after the original nominations were withdrawn. That removal did not place it on the 503A Bulks List or into Category 1, so it is not currently eligible for compounding. The Pharmacy Compounding Advisory Committee is reviewing these substances for the Bulks List; adding one requires formal rulemaking, which typically takes 12 to 24 months. See our regulatory status tracker and regulatory timeline for the current position.
Frequently asked questions
PEG-MGF (PEGylated Mechano Growth Factor) is a synthetic, polyethylene glycol-modified form of MGF, an IGF-1 splice variant released during mechanical muscle stress. It activates quiescent muscle satellite cells to promote muscle repair and hypertrophy.
In myoblast culture the MGF E-peptide promotes proliferation while mature IGF-1 drives differentiation, and the E-peptide does not act through the IGF-1 receptor the way mature IGF-1 does. Its actual receptor has not been definitively identified. The PEG modification is intended to shield the peptide from degradation, but no published pharmacokinetic study quantifies the resulting half-life.
Human safety data is limited. Reported side effects include injection site pain or swelling, hypoglycemia risk from IGF-1 pathway activity, water retention, and theoretical concern about accelerating existing neoplastic tissue growth. It is WADA-prohibited in competitive sport.
Both come from the IGF-1 axis, but they are not interchangeable and neither has human trial evidence. IGF-1 LR3 is a modified form of mature IGF-1 acting at the IGF-1 receptor; the MGF E-peptide is a different molecule that promotes myoblast proliferation rather than differentiation and does not act through that receptor in the same way. Community comparisons of their relative effects are not based on any published head-to-head study.
Research references
- The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarctionPubMed
- Administration of a synthetic peptide derived from the E-domain region of mechano-growth factor delays decompensation following myocardial infarctionPubMed
- Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarctionPubMed
- Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I)PubMed
- Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiationPubMed